Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the <scp>TRIUMPH</scp> study
Findings from this study showed that patients receiving galcanezumab had greater treatment effectiveness after 3 months than those receiving traditional oral migraine preventive medications across multiple measures, including migraine headache days, various responder rate thresholds, change in Migraine-Specific Quality of Life-Role Function Restrictive scores, and types of migraine. These findings are representative of clinical practice settings and may help physicians in making treatment decisions.
Authors
- R.L. Robinson (ORCID: https://orcid.org/0000-0003-1490-0491)
- Carlos R. Vallarino (ORCID: https://orcid.org/0000-0002-0929-2260)
- Zubair Ahmed (ORCID: https://orcid.org/0000-0002-7580-7453)
- Miguel J. A. Láinez (ORCID: https://orcid.org/0000-0003-3848-922X)
- Maurice Vincent (ORCID: https://orcid.org/0000-0001-5855-6069)
- Lars Viktrup (ORCID: https://orcid.org/0000-0002-8739-0544)
- Diego Novick
- Richard Lipton
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- Eli Lilly (United States) (US)
- University of Utah (US)
- Valencia Catholic University Saint Vincent Martyr (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Apex (Taiwan) (TW)
- Universidade Federal do Estado do Rio de Janeiro (BR)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1111/head.15045
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47